EU Animal-Test Ban Exceptions Offer Wiggle Room – Cosmetics Europe

Firms using multipurpose ingredients that required animal testing to comply with non-cosmetics-related regulations are safe under the EU’s animal-testing ban, suggests Gerald Renner, Cosmetics Europe’s director of technical regulatory affairs, at the in-cosmetics conference in Paris. However, it appears that animal testing to fulfill requirements in third countries, such as China, can not be applied toward compliance with European law.

Cosmetics Europe’s Gerald Renner provided the trade group’s perspective on the European Union’s cosmetic animal-testing ban during a Worldwide Regulatory Affairs Workshop at the in-cosmetics show in Paris, highlighting exceptions that provide some wiggle room for manufacturers.

As of March 11, the ban prohibits the use of animals in safety testing for cosmetic products and ingredients placed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By 

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By 

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By 

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

AESGP Annual Meeting: Commission Must ‘Think Carefully’ Before Reverse-Switching Antimicrobials

 
• By 

If the European Commission is serious about improving the competitiveness of the European Union, it should ditch the idea of making commonly used OTC antimicrobials like thrush treatments and cold sore creams prescription-only, warns Greek Medicines Agency president Evangelos Manolopoulos

More from Geography

AESGP Annual Meeting: Wastewater Directive Impact Assessment ‘Fundamentally Flawed’

 
• By 

AESGP president Jonathan Workman opens the 61st Annual Meeting with calls for industry unity in the face of the problematic revised EU Urban Wastewater Treatment Directive.

Over The Counter: Driving Innovation In France’s Self-Care Market, With NèreS’ Luc Besançon

 
• By 

HBW Insight speaks to NèreS' executive director Luc Besançon about the key issues facing France's self-care industry, especially Rx-to-OTC switch and the revised Urban Wastewater Treatment Directive.

‘We Must Have The Truth’ – Calls For UWWTD Review Intensify As Evidence Looks ‘Shaky’

 
• By 

The evidence underpinning the “polluter pays” principle of the revised Urban Wastewater Treatment Directive - which calls on Europe's pharmaceutical industry to cough up at least 80% of the cost of updating wastewater treatment facilities - is looking increasingly shaky, according to a new report.